Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

Market Cap	31.39B -8.8%
Revenue (ttm)	23.96B -2.8%
Net Income	2.03B +47.8%
EPS	1.24 +46.3%
Shares Out	1.63B
PE Ratio	15.49
Forward PE	13.33
Dividend	0.48 (2.50%)
Ex-Dividend Date	Aug 3, 2026

Volume	10,808,200
Open	19.18
Previous Close	19.18
Day's Range	19.01 - 19.32
52-Week Range	16.03 - 21.76
Beta	0.32
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 17,153
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600079

Financial Performance

In 2025, SHA:600079's revenue was 23.96 billion, a decrease of -5.79% compared to the previous year's 25.44 billion. Earnings were 1.86 billion, an increase of 39.53%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 9, 2026

Data Sources Report a data error